Skip to content
Bored Studies
RecruitingPhase 2

A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

Spyre Therapeutics, Inc. · NCT07766005

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
150
US sites recruiting
7
Study start
September 2026
Record last updated
October 19, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.

Being studied: SPY072; Placebo; bimekizumab

Conditions: Hidradenitis Suppurativa (HS)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Clinical diagnosis of Hidradenitis Suppurativa with symptoms for at least 6 months before screening.
  • Hidradenitis suppurativa lesions in at least 2 distinct anatomical areas, with at least 1 area meeting Hurley Stage II or III criteria at screening and Day 1.
  • Total abscess and/or inflammatory nodule count of at least 5 at screening and Day 1.
  • Documented inadequate response, intolerance, or contraindication to at least 1 systemic therapy for hidradenitis suppurativa.

Exclusion Criteria

  • More than 20 draining tunnels at screening or Day 1.
  • Hidradenitis suppurativa lesion expected to require incision and drainage within 4 weeks before Day 1, or major hidradenitis suppurativa surgery within 12 weeks before Day 1.
  • Another inflammatory or skin condition that could interfere with assessment of hidradenitis suppurativa.

Recruiting US locations

Study contacts (from the official record)

  • SKYLIGHT Trial Center · 1-702-602-7976 · info@SKYLIGHT-trial.com
All dermatology studies in Indiana →
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis… (NCT07766005) | Bored Studies